| abstract |
The invention relates to substituted bicyclic pyrroloheterocyclyl compounds of general formula (I), wherein A 1 and A 2 represent direct bond or C(=O), with the proviso that 0 or 1 of A 1 and A 2 represents C(=O); m and n independently denote 0, 1, 2 or 3, with the proviso that the sum [n + m] is 1, 2, 3 or 4; R 1 denotes H, F, CI, Br, I, CN, CF 3 , CF 2 H, CFH 2 , CO 2 H, CO 2 R 13 , R 13 , OH. O-R 13 , NH 2 , N(H)R 13 , N(R 13 ) 2 , R 2 represents 0 to 4 substituents, each independently selected from F, CI, Br, CN. CF 3 , CF 2 H, CFH 2 , R 13 , OH, O-R 13 , NH 2 , N(H)R 13 and N(R 13 ) 2 ; Ar 1 represents phenyl or 5- or 6-membered heteroaryl, in each case unsubstituted or substituted with one, two, three or four substituents, independently selected from F, CI, Br, CN, CF 3 . CF 2 H, CFH 2 , R 13 and O- R 13 ; or C 3-6 -cycloalkyl or 3 to 7 membered heterocycloalkyl, in each case unsubstituted or mono- or polysubstituted; Ar 2 represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or said heteroaryl may be unsubstituted or mono- or polysubstituted and may be condensed with a 4-, 5-, 6-or 7- membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be unsubstituted or mono- or polysubstituted; useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders. |